Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 8,137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Advanced Solid Tumors, Hematologic Malignancies
Interventions: IXAZOMIB; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Fairway, Kansas • Cleveland, Ohio • Dallas, Texas + 1 more

Conditions: Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy
Interventions: Zonisamide Oral Product; Drug
Lead sponsor: Azurity Pharmaceuticals; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Memphis, Tennessee

Conditions: Hemophilia
Interventions: rFVIII; Drug
Lead sponsor: Craig Seaman; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Pain, Musculoskeletal Pain
Interventions: LARKSPUR; Online Positive Emotions Skills for Individuals with Chronic Musculoskeletal Pain, Emotion Reporting Control Group; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depressive Disorder, Major
Interventions: saredutant (SR48968), paroxetine, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Interventions: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm), Fluorouracil/cisplatin (control arm); Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: Alexandria, Louisiana • Albuquerque, New Mexico • Dallas, Texas + 1 more

Conditions: Polypoidal Choroidal Vasculopathy
Interventions: ranibizumab 0.5 or 2.0 mg/0.05 cc; Drug
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Healthy Volunteers
Interventions: Meals; Dietary Supplement
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: surufatinib; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: PreDiabetes
Interventions: Physical Activity; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 30 Years to 64 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Aging
Interventions: Transcutaneous vagal nerve stimulation (tVNS), Cognitive training; Device · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 65 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Tucson, Arizona • Gainesville, Florida

Conditions: Smoking Cessation, Cigarette Smoking, Tobacco Use, Nicotine Dependence
Interventions: Mindful Smoking and Sensor-Band Intervention, Smoking Cessation Information; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: End Stage Renal Disease (ESRD)
Interventions: AMIA APD Solution Generation System; Device
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Jonesboro, Arkansas • San Jose, California • Jacksonville, Florida + 7 more

Conditions: Schizophrenia
Interventions: TAK-058, Ondansetron, TAK-058 Placebo, Ondansetron Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lung Inflammation, HIV Seropositivity
Interventions: ECIGS, mobile contingency management (mCM), Usual brand; Other · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HLA Sensitization
Interventions: plasmapheresis, Bortezomib, Rituximab, Methylprednisolone; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Injuries
Interventions: Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE- E) Bundle; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Post-operative Complications, Surgical Site Infection, Surgical Wound Infection
Interventions: Prevena™ Incision Management System (PIMS), Standard-of-care Dressing; Device
Lead sponsor: KCI USA, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Alessandro Doria; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 13
States / cities: Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more

Conditions: Neuroblastoma
Interventions: cyclophosphamide, Fludarabine, GINAKIT Cells; Drug · Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Biliary Cholangitis (PBC)
Interventions: Elafibranor, Matched 80 mg placebo; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 43
States / cities: Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more

Conditions: Healthy Participants
Interventions: TAK-954, Itraconazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Lichen Planopilaris of Scalp, Alopecia Areata
Interventions: Venus Glow; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 35 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Renal Insufficiency
Interventions: Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Search by objective public record fields.

Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction

Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

Weight-based Dosing in Hemophilia A

Lessons in Affect Regulation to Keep Stress and Pain UndeR Control (LARKSPUR R34)

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

ChronoMet: Metabolic and Inflammatory Effects of Eating Timing and Quantity

A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects

Influence of Exercise on the Gut Microbiome of Overweight and Obese Adults With Prediabetes

Non-invasive Nerve Stimulation and Cognitive Training to Improve Cognitive Performance in Healthy Older Adults

Quit With Sense: Using Mindful Smoking and Wearable Device for Smoking Cessation

Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers

Desensitization in Kidney Transplantation

Evaluating a Standardized Checklist Bundle for Optimizing Procedural Ergonomics in Endoscopy

The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants

Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Alopecias

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)